The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial

Abstract

Background Nephropathy in Diabetes type 2 (NID-2) study is an open-label cluster randomized clinical trial that demonstrated that multifactorial intensive treatment reduces Major Adverse Cardiac Events (MACEs) and overall mortality versus standard of care in type 2 diabetic subjects with albuminuria and no history of cardiovascular disease. Aim of the present post-hoc analysis of NID- 2 study is to evaluate whether the number of risk factors on target associates with patient outcomes. Methods Intervention phase lasted four years and subsequent follow up for survival lasted 10 years. To the aim of this post-hoc analysis, the whole population has been divided into 3 risk groups: 0–1 risk factor (absent/low); 2–3 risk factors (intermediate); 4 risk factors (high). Primary endpoint was a composite of fatal and non-fatal MACEs, the secondary endpoint was all-cause death at the end of the follow-up phase. Results Absent/low risk group included 166 patients (52.4%), intermediate risk group 128 (40.4%) and high-risk group 23 (7.3%). Cox model showed a significant higher risk of MACE and death in the high-risk group after adjustment for confounding variables, including treatment arm (HR 1.91, 95% CI 1.04–3.52, P = 0.038 and 1.96, 95%CI 1.02–3.8, P = 0,045, respectively, vs absent/low risk group). Conclusions This post-hoc analysis of the NID-2 trial indicates that the increase in the number of risk factors at target correlates with better cardiovascular-free survival in patients with type 2 diabetes at high CV risk. Clinical Trial Registration ClinicalTrials.gov number, NCT00535925. https://clinicaltrials.gov/ct2/show/NCT00535925

Impact of Lipoprotein(a) on Macrovascular Complications of Diabetes in a Multiethnic Population in the French Amazon

“…It should be noted that our population was relatively young (mean age = 55 years), and it is well known that cardiovascular complications in diabetes are associated with the duration of the disease (largely correlated with age), the presence of microvascular complications, and the number of nontargeted risk factors [23]. Here, we found a nonsignificant trend of increasing Lp(a) levels with age.…”

The association between distal symmetric polyneuropathy in diabetes with all-cause mortality – a meta-analysis

“…This increase was clearly present in both men and women and was independent of other major conventional vascular risk factors ( 2 ). In addition to the values of individual risk factors, the overall burden (estimated as the number of abnormal values) of risk factors showed a dose-response relationship with cardiovascular risk ( 3 ). Although diabetes patients with well-controlled conventional vascular risk factors have a comparable mortality risk to that of the background population ( 4 ), not all excess vascular and mortality risk can be explained by conventional vascular risk factors (such as smoking, hyperlipidemia, hypertension, etc.)…”

The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

“…Moreover, SGLT2 inhibitors increase fat utilization by activating M2 macrophages (42). Undoubtedly, the role of SGLT2 inhibitors in ameliorating cardiovascular risk relates not only to the adipose tissue reduction, but, to their pleiotropic effect in reducing multiple risk factors (43). There are some limitations to our study that should be noted.…”